Immatics Biotechnologies GmbH:企業の戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C13362)
◆英語タイトル:Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review
◆商品コード:DATA904C13362
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年2月
◆ページ数:30
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Immatics Biotechnologies GmbH – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of its drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH Key Recent Developments

Jan 11,2019: Immatics at the 18th PepTalk in San Diego, CA
Jan 03,2019: US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
Sep 28,2018: Immatics at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (Sept 30-Oct 3) in New York, NY
Aug 31,2018: Immatics to present at the Cell & Gene Therapy Bioprocessing & Commercialization 2018
Aug 31,2018: Immatics to present at the CAR-TCR Summit 2018 (Sept 4-7)

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Immatics Biotechnologies GmbH – Key Facts
Immatics Biotechnologies GmbH – Key Employees
Immatics Biotechnologies GmbH – Key Employee Biographies
Immatics Biotechnologies GmbH – Major Products and Services
Immatics Biotechnologies GmbH – History
Immatics Biotechnologies GmbH – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Immatics Biotechnologies GmbH – Business Description
Immatics Biotechnologies GmbH – SWOT Analysis
SWOT Analysis – Overview
Immatics Biotechnologies GmbH – Strengths
Immatics Biotechnologies GmbH – Weaknesses
Immatics Biotechnologies GmbH – Opportunities
Immatics Biotechnologies GmbH – Threats
Immatics Biotechnologies GmbH – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Immatics Biotechnologies GmbH, Recent Deals Summary
Section 4 – Company’s Recent Developments
Jan 11, 2019: Immatics at the 18th PepTalk in San Diego, CA
Jan 03, 2019: US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
Sep 28, 2018: Immatics at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (Sept 30-Oct 3) in New York, NY
Aug 31, 2018: Immatics to present at the Cell & Gene Therapy Bioprocessing & Commercialization 2018
Aug 31, 2018: Immatics to present at the CAR-TCR Summit 2018 (Sept 4-7)
Jul 16, 2018: Genmab and Immatics to develop bispecific cancer therapies
May 14, 2018: Immatics Appoints Stephen Eck as Chief Medical Officer US
Jan 17, 2018: Immatics Appoints Thomas Ulmer as CFO
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Immatics Biotechnologies GmbH, Key Facts
Immatics Biotechnologies GmbH, Key Employees
Immatics Biotechnologies GmbH, Key Employee Biographies
Immatics Biotechnologies GmbH, Major Products and Services
Immatics Biotechnologies GmbH, History
Immatics Biotechnologies GmbH, Other Locations
Immatics Biotechnologies GmbH, Subsidiaries
Immatics Biotechnologies GmbH, Key Competitors
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Immatics Biotechnologies GmbH, Recent Deals Summary

List of Figures
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Immatics Biotechnologies GmbH:企業の戦略的SWOT分析(Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆